Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 134 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Any Condition Clear all

Conditions: Primary Liver Cancer, Metastatic Liver Cancer From Any Cancer Site
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatocellular Carcinoma
Interventions: Regorafenib 40 MG; Drug
Lead sponsor: SC Liver Research Consortium, LLC; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 9
States / cities: Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more

Conditions: Any Condition in N73.0 Specified as Chronic, Adult Disease, Pharmacological Action
Interventions: Electronic Diaries, Hermeneutic Interviews; Other
Lead sponsor: Washington State University; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Spokane, Washington

Conditions: Lung Cancer
Interventions: sorafenib; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy, Rheumatoid Arthritis
Interventions: IA-14069, Placebo, Methotrexate; Drug
Lead sponsor: ILAb Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions: fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy; Radiation · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 24
States / cities: Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Any Condition Requiring Vulvar Biopsy
Interventions: EMLA, Lidocaine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Myelodysplastic Syndromes
Interventions: Azacitidine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza, Human, COVID-19
Interventions: Comirnaty, Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,442,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Solid Tumors), Cancer (With or Without Metastasis), Cancer - Ovarian, Cancer Abdomen, Cancer (Advanced Stage)
Interventions: Not listed
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Chambersburg, Pennsylvania • Ephrata, Pennsylvania • Gettysburg, Pennsylvania + 2 more

Conditions: A Diagnosis of Any Hematologic or Solid Malignancy
Interventions: Daily SMS text messaging; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Taking Benzodiazepines for Any Reason for 3 Months, Benzodiazepine Dependence
Interventions: EMPOWER-ED; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Major Depressive Disorder
Interventions: LY2216684, Fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Older Adults Without Any Specific Clinical Condition, Social Networks, RSV Immunization, Vaccine Uptake
Interventions: Motivate Aim: CHW text message reminders and counseling, Motivate Aim: CHW text message reminders only, Activate Aim: CHW text message reminders and counseling, Activate Aim: CHW text message reminders only; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Patients Indicated for a PICC for Any Medical Condition
Interventions: BioFlo™ Peripherally Inserted Central Catheter (PICC), Bard® Dual-Lumen PowerPICC SOLO2®; Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Evanston, Illinois • Louisville, Kentucky

Conditions: Breast Cancer
Interventions: PD0332991, Paclitaxel; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small Cell Lung Cancer
Interventions: Rociletinib Mono-Therapy, Erlotinib Mono-Therapy; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 54
States / cities: Birmingham, Alabama • Burbank, California • Duarte, California + 47 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more

Conditions: Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions: Enbrel; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Smyrna, Georgia

Conditions: Candidiasis, Oral, Thrush, Candidiasis
Interventions: Frio Oral Rinse; Drug
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Kansas City, Missouri • San Antonio, Texas

Conditions: Benign Prostatic Hyperplasia
Interventions: Dutasteride; Drug
Lead sponsor: Urologic Consultants of Southeastern PA; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bala-Cynwyd, Pennsylvania

Search by objective public record fields.

Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)

Optimization for Regorafenib in HCC

Medication-taking Preferences & Practices of Patients With Chronic Conditions

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

MAD Study of IA-14069

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

Pain Perception During Vulvar Biopsy

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

WellSpan-THRIVE Cancer QOL Study

ICanSTEP : Increasing Physical Activity With Text Messaging

Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults

The PROOF Study: The PICC Related Obstruction Of Flow Study

PD0332991/Paclitaxel in Advanced Breast Cancer

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Comparison of Blood Pressure Throughout Pregnancy

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart